Jeff Jorgensen - Concepedia

Author

Jeff Jorgensen

Also Known As

J. Jorgensen, Jeff Jorgensen, Jeff L. Jorgensen

Publications

539

Citations

H-Index

Concepts

All Affiliations

Jeff Jorgensen is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, hematology, and oncology.

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	373
2	Health Sciences	2	2	119
3	Biostatistics	1	1	65
4	Marrow Transplantation	1	1	65
5	Molecular Medicine	1	1	218

Jeff Jorgensen

Publications

516

Citations

H-Index

Page 1

	Year	Citations
COL4A2 Mutations Impair COL4A1 and COL4A2 Secretion and Cause Hemorrhagic Stroke Marion Jeanne, Cassandre Labelle‐Dumais, Jeff Jorgensen, The American Journal of Human Genetics Col4a2 SecretionHematologyPathologyCause Hemorrhagic StrokeNeurology	2011	218
Molecular and Genetic Analyses of Collagen Type IV Mutant Mouse Models of Spontaneous Intracerebral Hemorrhage Identify Mechanisms for Stroke Prevention Marion Jeanne, Jeff Jorgensen, Douglas B. Gould Circulation	2015	143
Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia Betül Oran, Jeff Jorgensen, David Marín, Haematologica Mixed-phenotype Acute LeukemiaTransplantation MedicinePathologyMyeloid NeoplasiaHematological Malignancy	2016	65
Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial Michael Wang, Preetesh Jain, Shuangtao Zhao, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaOncologyMantle Cell LymphomaSystemic Treatment	2022	54
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies Philip A. Thompson, Christine B. Peterson, Paolo Strati, Leukemia OncologyIndividualized Therapeutic StrategiesClinical TrialsPathologyMolecular Diagnostics	2018	36

Page 1